Insider Selling: Brunn Carsten, Selecta Biosciences Inc. [SELB] President and CEO divested 13,473 shares


Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Selecta Biosciences Inc. shares valued at $15,214 were sold by Brunn Carsten on Jan 05. At $1.13 per share, Brunn Carsten sold 13,473 shares. The insider’s holdings dropped to 786,013 shares worth approximately $1.12 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, TRABER PETER G sold 3,465 shares, netting a total of over 3,913 in proceeds. Following the sale of shares at $1.13 each, the insider now holds 446,121 shares.

Before that, Kishimoto Takashi Kei had sold 3,392 shares from its account. In a trade valued at $3,830, the Chief Scientific Officer traded Selecta Biosciences Inc. shares for $1.13 each. Upon closing the transaction, the insider’s holdings decreased to 3,392 shares, worth approximately $0.52 million.

As published in a research note from Needham on June 14, 2022, Selecta Biosciences Inc. [SELB] has been retained to a Buy and the price target has been revised to $5. This represents a 71.6% premium over Thursday’s closing price. Analysts at SVB Leerink started covering the stock with ‘”an Outperform”‘ outlook in a report released in early June. As of June 15, 2021, BTIG Research has initiated its “Buy” rating for SELB. Earlier on January 26, 2021, Mizuho upgraded its rating. Their new recommendation was “a Buy” for SELB stock which previously was a “a Neutral”.

Analyzing SELB Stock Performance

On Thursday, Selecta Biosciences Inc. [NASDAQ: SELB] rose 1.43% to $1.42. The stock’s lowest price that day was $1.3401, but it reached a high of $1.455 in the same session. During the last five days, there has been a drop of approximately -5.33%. Over the course of the year, Selecta Biosciences Inc. shares have jumped approximately 25.66%. Shares of the company reached a 52-week high of $1.9900 on 02/14/23 and a 52-week low of $1.0950 on 01/05/23. A 50-day SMA is recorded $1.6246, while a 200-day SMA reached $1.5722. Nevertheless, trading volume fell to 1.02 million shares from 1.32 million shares the previous day.

Support And Resistance Levels for Selecta Biosciences Inc. (SELB)

According to the 24-hour chart, there is a support level at 1.3551, which, if violated, would cause prices to drop to 1.2901. In the upper region, resistance lies at 1.4700. The next price resistance is at 1.5199. RSI (Relative Strength Index) is 38.20 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0819, which suggests the price will decrease in the coming days. Percent R is at 77.27%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Selecta Biosciences Inc. subject to short interest?

Stocks of Selecta Biosciences Inc. saw a sharp steep in short interest on Jan 12, 2023 dropping by 50000.0 shares to 6.02 million. Data from Yahoo Finance shows that the short interest on Dec 14, 2022 was 6.07 million shares. A decline of -0.83% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.36 of the overall float, the days-to-cover ratio (short ratio) decline to 8.36.

Which companies own the most shares of Selecta Biosciences Inc. (SELB)?

According to The Vanguard Group, Inc. filings, the company currently owns 6,313,315 shares, which is about 4.13% of the total SELB shares outstanding. The investor’s shares have appreciated by 216,226 from its previous 13-F filing of 6097089.0 shares. A total of 0 shares of Selecta Biosciences Inc. were sold by EcoR1 Capital, LLC during the quarter, and 101,798 were bought by BlackRock Fund Advisors. In its current portfolio, JPMorgan Asset Management holds 2,017,361 shares valued at $3.29 million.

In terms of Selecta Biosciences Inc. share price expectations, FactSet research, analysts set an average price target of $6.29 in the next 12 months, up nearly 328.57% from the previous closing price of $1.40. Analysts anticipate Selecta Biosciences Inc. stock to reach $9.00 by 2023, with the lowest price target being $4.00. In spite of this, 7 analysts ranked Selecta Biosciences Inc. stock as a Buy at the end of 2023.


Please enter your comment!
Please enter your name here